Cell Therapy Deals A "Strategic Priority" For Shire
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The recent earnings season was a reminder that Shire PLC, along with other specialist drug developers such as Celgene Inc., are comfortably positioned in a high-revenue-growth world that most big pharma have forgotten about.